Capricor Therapeutics Inc. Common Stock (CAPR)
Stock · NASDAQ · Health Care
$6.71as of 10/16/2026
Price chart
Active signals
CAPR Signal Track Record
How signals performed across all stocks →What CAPR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -2.7% | 45% | September 30, 2026 |
| Bollinger Band Breakout | 25 | -7.6% | 36% | August 26, 2026 |
| Bollinger Band Breakdown | 17 | -4.3% | 41% | October 5, 2026 |
| 200-Day Moving Average TouchActive now | 18 | -8.5% | 39% | July 6, 2026 |
| Any 20-session window (baseline) | -2.3% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The comp…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 231
- Website
- capricor.com/
Fundamentals
- 1-day range
- $6.96$7.4
- Market cap
- $242.07M
- P/E (trailing)
- —
- P/E (forward)
- -4.81
- EPS (trailing)
- $-2.45
- Dividend yield
- —
- Beta
- 0.56
- Avg. volume
- 6.88M
- Dividend pay date
- June 5, 2019
How Capricor Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 26, 2025 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Capricor Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CAPRCapricor Therapeutics Inc. Common Stock$6.71▼ 7.70%Market cap $242.07MP/E —$2.96$40.37
- SLGLSol-Gel Technologies Ltd. Ordinary Shares$64.25▼ 6.48%Market cap $244.18MP/E —$28.81$97.97
- PYXSPyxis Oncology Inc. Common Stock$1.68▼ 6.67%Market cap $237.58MP/E —$1.03$5.55
- ACIUAC Immune SA Common Stock$2.39▼ 2.45%Market cap $236.11MP/E —$2.1$4
- WHWKWhitehawk Therapeutics Inc. Common Stock$2.89▼ 4.93%Market cap $252.78MP/E —$1.97$5.5
- MGNXMacroGenics Inc. Common Stock$3.25▼ 3.56%Market cap $254.89MP/E —$1.29$5.08
- AKBAAkebia Therapeutics Inc. Common Stock$0.67▼ 3.74%Market cap $256.03MP/E —$0.7$3.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CAPR Capricor Therapeutics Inc. Common Stock | $242.07M | — | $6.71 | ▼ 7.70% | $2.96$40.37 |
| SLGL Sol-Gel Technologies Ltd. Ordinary Shares | $244.18M | — | $64.25 | ▼ 6.48% | $28.81$97.97 |
| PYXS Pyxis Oncology Inc. Common Stock | $237.58M | — | $1.68 | ▼ 6.67% | $1.03$5.55 |
| ACIU AC Immune SA Common Stock | $236.11M | — | $2.39 | ▼ 2.45% | $2.1$4 |
| WHWK Whitehawk Therapeutics Inc. Common Stock | $252.78M | — | $2.89 | ▼ 4.93% | $1.97$5.5 |
| MGNX MacroGenics Inc. Common Stock | $254.89M | — | $3.25 | ▼ 3.56% | $1.29$5.08 |
| AKBA Akebia Therapeutics Inc. Common Stock | $256.03M | — | $0.67 | ▼ 3.74% | $0.7$3.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In JapanYahoo · 10/1/2026
- Which stocks are gapping on Wednesday?ChartMill · 9/30/2026
- Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' ScenarioSeekingAlpha · 9/30/2026
- Capricor Therapeutics Stock Surges: What's Going On?Benzinga · 9/30/2026
- Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On WednesdayBenzinga · 9/30/2026
- Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving PremarketBenzinga · 9/30/2026
- Why Did CAPR Stock Jump 20% After-Hours Today?Yahoo · 9/30/2026
- Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst RevisionsYahoo · 9/23/2026
Insider Activity
Insider Actions →- Bergmann Anthony · June 24, 2026 · Option Exercise400 @ $3.18
- Bergmann Anthony · June 24, 2026 · Sale400 @ $30
- Krasney Karen · June 24, 2026 · Option Exercise400 @ $3.18
- Krasney Karen · June 24, 2026 · Sale400 @ $30
- Bergmann Anthony · June 22, 2026 · Option Exercise500 @ $3.18
- Bergmann Anthony · June 22, 2026 · Sale500 @ $30
- Krasney Karen · June 22, 2026 · Option Exercise500 @ $3.18
- Krasney Karen · June 22, 2026 · Sale500 @ $30
- Maurer Michael T · May 26, 2026 · Grant80.0K
- Bergmann Anthony · May 18, 2026 · Option Exercise3.0K @ $1.39
- Litvack Frank · May 13, 2026 · Option Exercise3.9K @ $1.39
- Bergmann Anthony · May 1, 2026 · Option Exercise25.0K @ $3.18
- Bergmann Anthony · May 1, 2026 · Sale25.0K @ $31.7
- Krasney Karen · May 1, 2026 · Option Exercise25.0K @ $3.18
- Krasney Karen · May 1, 2026 · Sale25.0K @ $31.7
Institutional Ownership
March 31, 2026
- Total shares held
- 37.60M
- Total value held
- $1.14B
- Institutional holders
- 175
- Unknown3.82M
- Unknown3.42M
- Unknown3.40M
- Unknown2.18M
- Unknown2.03M
- Unknown1.51M
- Unknown1.44M
- Unknown1.37M
- Unknown1.12M
- Unknown1.03M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Capricor Therapeutics Sees Fair Value Adjustments on Deramiocel
Analysts have revised their fair value estimates for Capricor Therapeutics following new data on its lead candidate, Deramiocel. These adjustments reflect updated expectations for the drug's potential, which may influence how investors view the company's long-term outlook. The stock currently trades within a wide 52-week range, indicating significant volatility tied to these clinical developments.
Capricor Therapeutics Sees Fair Value Adjustments on Deramiocel. Analysts have revised their fair value estimates for Capricor Therapeutics following new data on its lead candidate, Deramiocel. These adjustments reflect updated expectations for the drug's potential, which may influence how investors view the company's long-term outlook. The stock currently trades within a wide 52-week range, indicating significant volatility tied to these clinical developments.